JP2005523687A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523687A5
JP2005523687A5 JP2003557507A JP2003557507A JP2005523687A5 JP 2005523687 A5 JP2005523687 A5 JP 2005523687A5 JP 2003557507 A JP2003557507 A JP 2003557507A JP 2003557507 A JP2003557507 A JP 2003557507A JP 2005523687 A5 JP2005523687 A5 JP 2005523687A5
Authority
JP
Japan
Prior art keywords
tumor
tm7xn1
moiety
compound
astrocytoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003557507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/041419 external-priority patent/WO2003057148A2/en
Publication of JP2005523687A publication Critical patent/JP2005523687A/ja
Publication of JP2005523687A5 publication Critical patent/JP2005523687A5/ja
Pending legal-status Critical Current

Links

JP2003557507A 2001-12-27 2002-12-23 腫瘍の処置及び可視化における生体分子標的の使用法 Pending JP2005523687A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34342201P 2001-12-27 2001-12-27
PCT/US2002/041419 WO2003057148A2 (en) 2001-12-27 2002-12-23 Use of biomolecular targets in the treatment and visualization of tumors

Publications (2)

Publication Number Publication Date
JP2005523687A JP2005523687A (ja) 2005-08-11
JP2005523687A5 true JP2005523687A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=23346050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003557507A Pending JP2005523687A (ja) 2001-12-27 2002-12-23 腫瘍の処置及び可視化における生体分子標的の使用法

Country Status (6)

Country Link
US (3) US7014838B2 (cg-RX-API-DMAC10.html)
EP (1) EP1465997A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005523687A (cg-RX-API-DMAC10.html)
AU (1) AU2002360773A1 (cg-RX-API-DMAC10.html)
CA (1) CA2469480A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003057148A2 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005073621A (ja) * 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
US20050255045A1 (en) * 2004-05-13 2005-11-17 Woltering Eugene A Surgical marking composition and method
EP2471924A1 (en) 2004-05-28 2012-07-04 Asuragen, INC. Methods and compositions involving microRNA
WO2006020557A2 (en) * 2004-08-10 2006-02-23 Immusol, Inc. Methods of using or identifying agents that inhibit cancer growth
ES2534300T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
JPWO2006051984A1 (ja) * 2004-11-15 2008-05-29 キリンファーマ株式会社 癌細胞の転移抑制方法およびそのために使用する医薬組成物
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
CA2664383C (en) * 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
EP2145001A2 (en) * 2006-09-19 2010-01-20 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
EP2104735A2 (en) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CN101622348A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
EP2104737B1 (en) * 2006-12-08 2013-04-10 Asuragen, INC. Functions and targets of let-7 micro rnas
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
US20090253780A1 (en) * 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US20100074480A1 (en) 2008-09-22 2010-03-25 University Of Washington Device for generating alternative of normal brain database
CA2738124A1 (en) * 2008-09-22 2010-03-25 Nihon Medi-Physics Co., Ltd. Device for creating database of alternative normal brain
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
US9222085B2 (en) 2011-02-03 2015-12-29 Mirna Therapeutics, Inc. Synthetic mimics of MIR-124
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
WO2015143074A1 (en) * 2014-03-20 2015-09-24 University Of Southern California Brain cancer immunotherapy
US12358959B2 (en) 2016-03-31 2025-07-15 Children's Medical Center Corporation Compositions and methods for oligodendrocyte development

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030167485A1 (en) * 1997-09-24 2003-09-04 Garvan Institute Of Medical Research Novel G protein-coupled receptor encoding gene and diagnostic uses therefor
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
WO2000020590A2 (en) 1998-10-06 2000-04-13 Incyte Pharmaceuticals, Inc. G-protein coupled receptor proteins
EP1033404A1 (en) * 1999-01-29 2000-09-06 F. Hoffmann-La Roche Ag New gene with down-regulated expression in metastatic human melanoma cells

Similar Documents

Publication Publication Date Title
Chen et al. Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
JP2025041675A (ja) リソソーム標的化のための二官能性分子ならびに関連する組成物および方法
Spenlé et al. Tenascin-C: Exploitation and collateral damage in cancer management
Grünwald et al. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene
Spitzweg et al. The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment
Li et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas
Dorst et al. Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis
Vandergrift et al. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas
Jia et al. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer
Kasten et al. Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model
JP2014504149A (ja) 治療と併用する癌画像診断:セラノスティックス
Shih et al. 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma
Achmad et al. Predicting cetuximab accumulation in KRAS wild‐type and KRAS mutant colorectal cancer using 64Cu‐labeled cetuximab positron emission tomography
Petronzelli et al. Therapeutic use of avidin is not hampered by antiavidin antibodies in humans
Simons et al. PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool
You et al. Molecular magnetic resonance probe targeting VEGF165: preparation and in vitro and in vivo evaluation
Taha et al. Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy
CN111615518B (zh) 阻断emt途径并克服癌干细胞的il8
JP2001513111A (ja) 腫瘍付随血管(tumor−associated blood vessels)上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート
Li et al. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo
Tan et al. Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities
De Bonis et al. Radioimmunotherapy for high-grade glioma
Apparailly et al. Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis
Zhang et al. Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging
JP2004537282A5 (cg-RX-API-DMAC10.html)